Literature DB >> 2999279

Serum activity and hepatic secretion of lecithin:cholesterol acyltransferase in experimental hypothyroidism and hypercholesterolemia.

N D Ridgway, P J Dolphin.   

Abstract

Lecithin:cholesterol acyltransferase (LCAT), the major cholesterol esterifying enzyme in plasma, plays an important role in the removal of cholesterol from peripheral tissues. This study in rat focuses upon the effects of hypothyroidism and cholesterol feeding on serum activity and hepatic LCAT secretion. To obviate the effect that inclusion of high concentrations of cholesterol in the rat serum may have on the proteoliposome used in the assay of LCAT, very low and low density lipoproteins (VLDL and LDL) were removed by ultracentrifugation at d 1.063 g/ml. The molar esterification rate in the euthyroid VLDL + LDL-free serum was found to be 0.94 +/- 0.06 compared to 0.67 +/- 0.05 in hypothyroid rats and 1.56 +/- 0.14 in hypercholesterolemic rats. LCAT secretion by suspension cultures of hepatocytes from hypercholesterolemic rats was found to be significantly depressed when compared to that for euthyroid and hypothyroid animals. Secretion by hepatocytes from hypothyroid rats was depressed for the first 0-4 hr, but rapidly recovered. The depressed secretion of LCAT by hepatocytes from hypercholesterolemic rats correlates with the appearance in the media of apoE-rich, discoidal HDL. Discoidal HDL was six times more effective as a substrate for purified human LCAT than HDL from hypercholesterolemic serum, and twice as effective as serum and nascent HDL from euthyroid animals. It is concluded that the depressed LCAT activity in serum from hypothyroid rats is due to a depressed hepatic secretion of the enzyme and that the elevated serum activity of hypercholesterolemic rats may be related to a defect in LCAT clearance. Finally, the appearance of discoidal HDL in the medium upon culture of hepatocytes from hypercholesterolemic rats appears to be due to an inhibition of LCAT secretion by these cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999279

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  4 in total

1.  Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.

Authors:  Gary J Grover; Karin Mellström; Liu Ye; Johan Malm; Yi-Lin Li; Lars-Göran Bladh; Paul G Sleph; Mark A Smith; Rocco George; Björn Vennström; Kasim Mookhtiar; Ryan Horvath; Jessica Speelman; Donald Egan; John D Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-29       Impact factor: 11.205

2.  Pleiotropic effects of thyroid hormones: learning from hypothyroidism.

Authors:  Martha Franco; Edmundo Chávez; Oscar Pérez-Méndez
Journal:  J Thyroid Res       Date:  2011-06-27

Review 3.  Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism.

Authors:  Huixing Liu; Daoquan Peng
Journal:  Endocr Connect       Date:  2022-02-07       Impact factor: 3.335

4.  Serum Lipidome Signatures of Dogs with Different Endocrinopathies Associated with Hyperlipidemia.

Authors:  Nadja S Sieber-Ruckstuhl; Wai Kin Tham; Franziska Baumgartner; Jeremy John Selva; Markus R Wenk; Bo Burla; Felicitas S Boretti
Journal:  Metabolites       Date:  2022-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.